.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,110,900

« Back to Dashboard

Details for Patent: 6,110,900

Title: Nucleic acid ligands
Abstract:This invention comprises nucleic acid ligand for use as a diagnostic reagent for detecting the presence or absence of a target molecule in a sample, and a diagnostic reagent to measure the amount of a target molecule in a sample. In a preferred embodiment the nucleic acid ligands are identified by the method of the invention referred to as the Systematic Evolution of Ligands by EXponential enrichment (SELEX), wherein a candidate mixture of nucleic acids are iteratively enriched in high affinity nucleic acids and amplified by further partitioning.
Inventor(s): Gold; Larry (Boulder, CO), Tuerk; Craig (Morehead, KY)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Aug 27, 1998
Application Number:09/143,190
Claims:1. A diagnostic composition comprising a nucleic acid ligand.

2. The diagnostic composition of claim 1 wherein said nucleic acid ligand is single-stranded.

3. The diagnostic composition of claim 2 wherein said nucleic acid ligand is ribonucleic acid.

4. The diagnostic composition of claim 2 wherein said nucleic acid ligand is deoxyribonucleic acid.

5. The diagnostic composition of claim 1 wherein said nucleic acid ligand is labeled.

6. The diagnostic composition of claim 5 wherein said label is a radiolabel.

7. The diagnostic composition of claim 1 wherein said nucleic acid ligand binds to a target molecule that is a protein.

8. The diagnostic composition of claim 7 wherein said protein is not known to bind nucleic acids as part of its biological function.

9. The diagnostic composition of claim 1 wherein said nucleic acid ligand binds to a target molecule that is a small molecule.

10. The diagnostic composition of claim 1 wherein said nucleic acid ligand binds to a target molecule that is a controlled substance.

11. The diagnostic composition of claim 1 wherein said nucleic acid ligand binds to a target molecule that is a metabolite.

12. The diagnostic composition to claim 1 wherein said nucleic acid ligand binds to a target molecule that is a biological substance.

13. A diagnostic composition comprising a nucleic acid ligand to a target molecule, said nucleic acid ligand being identified from a candidate mixture of nucleic acids by a method comprising:

(a) contacting the candidate mixture with said target molecule, wherein nucleic acids having an increased affinity to said target molecule relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

(b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and

(c) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids, wherein an increased affinity nucleic acid ligand may be identified.

14. The diagnostic composition of claim 13 wherein said nucleic acid ligand is identified after repeating steps (a), (b) and (c) at least once.

15. The diagnostic composition of claim 13 wherein the nucleic acid ligand is single-stranded.

16. The diagnostic composition of claim 15 wherein the nucleic acid ligand is ribonucleic acid.

17. The diagnostic composition of claim 15 wherein the nucleic acid is deoxyribonucleic acid.

18. The diagnostic composition of claim 13 wherein the target molecule is a protein.

19. The diagnostic composition of claim 18 wherein said protein is not known to bind nucleic acids as part of its biological function.

20. The diagnostic composition of claim 13 wherein said target molecule is a controlled substance.

21. The diagnostic composition of claim 13 wherein said target molecule is a metabolite.

22. The diagnostic composition of claim 13 wherein said target molecule is a small molecule.

23. The diagnostic composition of claim 13 wherein said candidate mixture is prepared by synthesis from a template comprising a region of conserved sequence and a region of randomized and/or biased sequence.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc